Stereotaxis (STXS) Q3 2024 earnings summary

Executive summary

• Achieved 18% year-over-year revenue growth in Q3 2024 to $9.2 million, driven by Genesis system sales and the integration of the APT acquisition.

• Completed and integrated the APT acquisition, expanding the product portfolio, manufacturing capabilities, and commercial reach.

• Advanced regulatory milestones for Genesis X and MAGIC ablation catheter in Europe, US, and China.

• Strong commercial momentum in Europe, with a robust pipeline and growing interest in other geographies.

• Company continues to face macroeconomic and supply chain challenges impacting operations and customer purchasing cycles.

Financial highlights

• Q3 2024 revenue was $9.2 million, up from $7.8 million in Q3 2023; system revenue $4.4 million, recurring revenue $4.8 million.

• Gross margin was 45%, down from 52% in Q3 2023, due to product mix and acquisition-related adjustments.

• Operating loss was $6.3 million; net loss was $6.2 million; adjusted operating loss $3.1 million.

• Cash and equivalents were $11 million at quarter-end, rising to $13.3 million by end of October; no debt.

• Negative free cash flow for Q3 was $4.2 million.

Outlook and guidance

• Full-year 2024 revenue expected to be approximately flat year-over-year, with anticipated growth in system and recurring revenue in coming quarters.

• Expects to end 2024 with ~$12 million in cash and no debt, sufficient to fund commercialization and reach profitability without additional financing.

• No plans for shareholder dilution at current valuation; focus on prudent financial management.

• Management expects continued challenges from supply chain disruptions, inflation, and hospital capital constraints.